

Medical Policy



An Independent Licensee of the
Blue Cross and Blue Shield Association

Title: Identification of Microorganisms Using Nucleic Acid Probes

Professional

Original Effective Date: July 8, 2008
Revision Date(s): June 16, 2009
Current Effective Date: June 16, 2009

Institutional

Original Effective Date: July 16, 2009
Revision Date(s):
Current Effective Date: July 16, 2009

DESCRIPTION

Until recently, identification of microorganisms depended either on culture of body fluids or tissues or identification of antigens, using a variety of techniques including direct fluorescent antibody technique and qualitative or quantitative immunoassays. These techniques are problematic when the microorganism exists in very small numbers or is technically difficult to culture. Indirect identification of microorganisms by immunoassays for specific antibodies reactive with the microorganism is limited by difficulties in distinguishing between past exposure and current infection; although to some extent IgM versus IgG antibodies can be helpful. Response to treatment is typically assessed according to the patient's clinical response or by rising titers of specific antibodies and falling antigen titers.

Recently, the availability of nucleic acid probes has permitted the rapid direct identification of microorganisms' DNA or RNA. Amplification techniques, including but not limited to the polymerase chain reaction (PCR), results in exponential increases in copy numbers of a targeted strand of microorganism-specific DNA. After amplification, target DNA can be readily detected using a variety of techniques. The amplified product can also be quantified to give an assessment of how many microorganisms are present. Quantification of the amount of nucleic acids permits serial assessments of response to treatment; the most common clinical application of quantification is the serial measurement of HIV RNA (called viral load), which serves as a prognostic factor.

Until 1998, these nucleic acid probe techniques were coded using nonspecific CPT codes describing the multiple steps in the laboratory process. However, in 1998, the CPT codes were revised to include a series of new codes that describe the direct probe technique, amplified probe technique, and quantification for 22 different microorganisms. These series of CPT codes were introduced as a group; however, at present, probe technologies and clinical applications for some microorganisms are either not widely disseminated or are used primarily for research purposes. In addition, CPT codes have been added for additional microorganisms, such as *Staphylococcus aureus*.

POLICY

The status of nucleic acid identification using direct probe, amplified probe, or quantification for microorganisms is summarized as follows:

Microorganism	Direct Probe	Amplified Probe	Quantification
Bartonella henselae or quintana	87470 (inv)	87471 (inv)	87472 (inv)
Borrelia burgdorferi	87475 (inv)	87476 (inv)	87477 (inv)
Candida species	87480 (med nec)	87481 (inv)	87482 (inv)
Chlamydia pneumoniae	87485 (inv)	87486 (inv)	87487 (inv)
Chlamydia trachomatis	87490 (med nec)	87491 (med nec)	87492 (inv)
Cytomegalovirus	87495 (med nec)	87496 (med nec)	87497 (med nec)
Enterovirus		87498 (inv)	
Gardnerella vaginalis	87510 (med nec)	87511 (inv)	87512 (inv)
Hepatitis B	87515 (med nec)	87516 (med nec)	87517 (med nec)
Hepatitis C	87520 (med nec)	87521 (med nec)	87522 (med nec)
Hepatitis G	87525 (inv)	87526 (inv)	87527 (inv)
Herpes simplex virus	87528 (med nec)	87529 (med nec)	87530 (inv)
Herpes virus-6	87531 (inv)	87532 (inv)	87533 (inv)
HIV-1	87534 (med nec)	87535 (med nec)	87536 (med nec)
HIV-2	87537 (med nec)	87538 (med nec)	87539 (med nec)
Legionella pneumophila	87540 (inv)	87541 (inv)	87542 (inv)
Mycobacterium species	87550 (med nec)	87551 (inv)	87552 (inv)
Mycobacterium tuberculosis	87555 (med nec)	87556 (med nec)	87557 (inv)
Mycobacterium avium intracellulare	87560 (med nec)	87561 (inv)	87562 (inv)
Neisseria gonorrhoeae	87590 (med nec)	87591 (med nec)	87592 (inv)
Papillomavirus	87620 (med nec)	87621 (med nec)	87622 (inv)
Staphylococcus aureus		87640 (med nec)	
Staphylococcus aureus, methicillin resistant		87641 (med nec)	
Streptococcus group A*	87650 (med nec)	87651 (inv)	87652 (inv)
Streptococcus group B		87653 (med nec)	
Vancomycin resistance (e.g., enterococcus vanA, vanB)		87500 (med nec)	

CODING

The following codes for treatment and procedures applicable to this policy are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

CPT/HCPCS

See Policy section.

CPT codes 87797, 87798, and 87799 describe the use of direct probe, amplified probe, and quantification, respectively, for infectious agents not otherwise specified. It should be noted that the technique for quantification includes both amplification and direct probes; therefore, simultaneous coding for both quantification with either amplification or direct probes, is not warranted.

DIAGNOSIS

010.0-	Tuberculosis (code range)
018.9	
030.0-	Other bacterial diseases; Leprosy (code range)
030.9	
031.0-	Other bacterial diseases; Diseases due to other mycobacteria (code range)
031.9	
054.0-	Viral diseases accompanied by Exanthem; Herpes simplex (code range)
054.9	
070.20-	Other diseases due to viruses and chlamydiae; Viral hepatitis B (code range)
070.33	
070.41	Acute or unspecified hepatitis C with hepatic coma
070.44	Chronic hepatitis C with hepatic coma
070.51	Acute or unspecified hepatitis C without mention of hepatic coma
070.54	Chronic hepatitis C without mention of hepatic coma
078.5	Cytomegaloviral disease
079.88	Other specified chlamydial infection
079.89	Other specified viral infections (includes papillomavirus)
079.98	Unspecified chlamydial infection
098.0-	Gonococcal infections (code range)
098.89	
482.84	Legionnaires' disease
771.1	Congenital cytomegalovirus infection
771.2	Other congenital infections (includes herpes simplex, tuberculosis)
V08	Human immunodeficiency virus (HIV) asymptomatic
V28.6	Antenatal screening for Streptococcus B

REFERENCES

1. Shelhamer JH, Gill VJ, Quinn TC et al. The laboratory evaluation of opportunistic pulmonary infections. *Ann Intern Med* 1996; 124(6):585-99.
2. Feldman SR, Lye KD, Smith ES et al. Polymerase chain reaction and its application for the diagnosis and management of skin diseases. *Adv Dermatol* 1997; 12:115-37.

3. Cinque P, Cleator GM, Weber T et al. The role of laboratory investigation in the diagnosis and management of patients with suspected herpes simplex encephalitis: a consensus report. *J Neurol Neurosurg Psychiatry* 1996; 61(4):339-45.
4. Schmidt BL. PCR in laboratory diagnosis of human *Borrelia burgdorferi* infections. *Clin Microbiol Rev* 1997; 10(1):185-201.
5. Boivin G, Belanger R, Delage R et al. Quantitative analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay and the COBAS AMPLICOR CMV MONITOR PCR test after blood and marrow allogeneic transplantation. *J Clin Microbiol* 2000; 38(12):4356-60.
6. Weinberg A, Hodges TN, Li S et al. Comparison of PCR, antigenemia assay and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation. *J Clin Microbiol* 2000; 38(2):768-72.
7. Humar A, Gregson D, Caliendo AM et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. *Transplantation* 1999; 68(9):1305-11.
8. Li H, Dummer JS, Estes WR et al. Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients. *J Clin Microbiol* 2003; 41(1):187-91.
9. Razonable RR, van Crujisen H, Brown RA et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. *J Infect Dis* 2003; 187(11):1801-8.
10. Wolters LM, Hansen BE, Niesters HG et al. Viral dynamics in chronic hepatitis B patients during lamivudine therapy. *Liver* 2002; 22(2):121-6.
11. Zollner B, Schafer P, Feucht HH et al. Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. *J Med Virol* 2001; 65(4):659-63.
12. Buti M, Sanchez F, Cotrina M et al. Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B. *J Infect Dis* 2001; 183(8):1277-80.
13. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. *Hepatology* 2002; 36(6):1408-15.
14. Ganem D, Prince AM. Hepatitis B virus infection – Natural history and clinical consequences. *N Engl J Med* 2004; 350(11):1118-29.
15. Abba MC, Mouron SA, Gomez MA et al. Association of human papilloma viral load with HPV16 and high-grade intraepithelial lesion. *Int J Gynecol Cancer* 2003; 13(2):154-8.
16. Lorincz AT, Castle PE, Sherman ME et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. *Lancet* 2002; 360(9328):228-9.
17. Schlecht NF, Trevisan A, Duarte-Franco E et al. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. *Int J Cancer* 2003; 103(4):519-24.
18. Ylitalo N, Sorensen P, Josefsson AM et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. *Lancet* 2000; 355(9222):2194-8.
19. Josefsson AM, Magnusson PK, Ylitalo N et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. *Lancet* 2000; 355(9222):2189-93.
20. Package Insert, Gen-Probe: Group A Streptococcus Direct Test.
21. Bergeron MG, Ke D, Menard C et al. Rapid detection of group B streptococci in pregnant women at delivery. *N Engl J Med* 2000; 343(3):175-9.

22. Bergeron MG, Ke D. New DNA-based PCR approaches for rapid real-time detection and prevention of group B streptococcal infections in newborns and pregnant women. *Expert Rev Mol Med* 2001; 2001:1-14.
23. Kaplan S, Marlowe EM, Hogan JJ et al. Sensitivity and specificity of a rapid rRNA gene probe assay for simultaneous identification of *Staphylococcus aureus* and detection of *mecA*. *J Clin Microbiol* 2005; 43(7):3438-42.
24. Zhang K, Sparling J, Chow BL et al. New quadriplex PCR assay for detection of methicillin and mupirocin resistance and simultaneous discrimination of *Staphylococcus aureus* from coagulase-negative staphylococci. *J Clin Microbiol* 2004; 42(11):4947-55.
25. Appleman MD, citron DM, Kwok R. Evaluation of the Velogene genomic assay for detection of *vanA* and *vanB* genes in vancomycin-resistant *Enterococcus* species. *J Clin Microbiol* 2004; 42(4):1751-2.
26. Patel R, Uhl JR, Kohner P et al., Multiplex PCR detection of *vanA*, *vanB*, *vanC-1*, and *vanC-2/3* genes in enterococci. *J Clin Microbiol* 1997;35(3):703-7.